How to appeal an Aetna bone marrow transplant (allogeneic hsct) denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Aetna-specific note: Owned by CVS Health since 2018. CVS Caremark is the PBM. Aetna ASA administers self-funded ERISA plans. Meritain Health is Aetna's TPA brand.

What Aetna's policy requires for bone marrow transplant (allogeneic hsct)

Cited policy: Aetna Clinical Policy Bulletin - Hematopoietic Stem Cell Transplantation (Allogeneic) — Conditioning Intensity

Covered indications per CMS NCD 110.8.1 + NCCN AML/MDS/ALL/MM transplant sections. RIC permitted for HCT-CI ≥3, age ≥55-60, organ dysfunction precluding MAC. Conditioning regimen documented (Flu/Mel, Flu/Bu, Flu/TBI 200/400). Pre-transplant evaluation by BMT-trained hematologist-oncologist.

How Aetna denies bone marrow transplant (allogeneic hsct) — and how to counter it

Where Aetna pushes back: 1) Patient too old (>65) — transplant not safe; 2) MAC indicated regardless of HCT-CI; 3) RIC inadequate for high-risk disease; 4) Pre-transplant cardiac/pulmonary clearance insufficient.

Counter-arguments that hold up: RIC (Flu/Mel, Flu/Bu, Flu/TBI 400) has extended allo-HSCT eligibility to age 75+. Sorror HCT-CI (Blood 2005;106:2912) — comorbidity-adjusted risk supersedes chronologic age. BMT CTN 0901 (Scott JCO 2017;35:1154) — RIC vs MAC AML/MDS — for fit patients MAC superior, but RIC remains standard for HCT-CI ≥3 / older / unfit. NCCN AML v2.2024 + MDS v3.2024 + ASTCT consensus endorse RIC selection. Document HCT-CI + EBMT risk score + organ function (EF, DLCO, CrCl). Pre-transplant evaluation completed per ASTCT framework.

What Aetna typically denies for bone marrow transplant (allogeneic hsct)

Across Aetna's commercial and Medicare books, denials cluster around a small number of patterns. For bone marrow transplant (allogeneic hsct), expect:

• UM-2575 medical necessity denials
• Prior auth absent
• Step therapy on specialty drugs
• Out-of-network ER reduction

Treatments most often denied in this category

These are the bone marrow transplant (allogeneic hsct) treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Allo-HSCT (MAC)
• Allo-HSCT (RIC)
• Allo-HSCT (NMA)
• MRD allo-HSCT
• MUD allo-HSCT
• Haplo allo-HSCT

How to submit the appeal to Aetna

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Aetna cited in the denial.
3. File the appeal through Aetna's portal (members: https://www.aetna.com ; providers: https://www.aetnaprovider.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In CT, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Aetna's prior-authorization criteria by drug: Aetna PA criteria on ApprovalHelp.